...
首页> 外文期刊>BMC Immunology >Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations
【24h】

Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations

机译:来自结肠癌患者的肿瘤内调节性T细胞包含几种活化的效应群体

获取原文

摘要

Intratumoral regulatory T cells (Treg) in colon cancer are a heterogeneous cell population, with potential impact on patient outcome. Generally, a high Treg infiltration has been correlated to a worse patient outcome, but it is still unclear how the composition of different Treg subsets affects patient relapse and survival. In this study, we used mass and flow cytometry to characterize Treg in colon tumors and corresponding unaffected tissue, followed by a correlation to clinical parameters and patient outcome. Using mass cytometry, we defined 13 clusters of intestinal Treg, three of which were enriched in the tumors. The two most enriched clusters were defined by their expression of the proliferation marker Ki67 and CD56, respectively. The Treg accumulating in the tumors expressed inducible T-cell co-stimulator (ICOS), OX-40, and CD39, indicating that they were effector Treg (eTreg). Intratumoral CD39 Treg also had a higher expression of Foxp3, suggesting a higher suppressive activity, and we subsequently used CD39 as a marker for eTreg. Our further studies showed that colon tumors can be divided into two tumor groups, based on the proportion of CD39 putative eTreg in the tumors. This property was independent of both tumor microsatellite status and tumor stage, which are important factors in predicting cancer disease progression. In a prospective study of forty-four colon cancer patients, we also showed that patients with a high CD39 expression on tumor-infiltrating Treg have a tendency towards a less favorable patient outcome in terms of cumulative cancer-specific survival. This study uncovers novel subsets of tumor-infiltrating Treg in colon cancer, and suggests that CD39 may be a potential therapeutic target in patients with microsatellite stable colon tumors, which are usually refractory to checkpoint blockade therapy.
机译:结肠癌中的肿瘤内调节性T细胞(Treg)是异质细胞群,对患者结果产生潜在的影响。通常,高Treg渗透与较差的患者结果相关,但尚不清楚不同Treg子集的组成如何影响患者复发和存活率。在该研究中,我们使用质量和流式细胞术在结肠肿瘤中表征Treg和相应的未受影响的组织,然后与临床参数和患者结果相关。使用质量细胞术,我们定义了13个肠道肠道簇,其中三种肠道富集在肿瘤中。两种最富集的簇分别由它们的增殖标志物Ki67和CD56的表达定义。在肿瘤中积聚的Treg表达诱导型T细胞共刺激器(ICOS),OX-40和CD39,表明它们是效应Treg(etreg)。肿瘤内CD39 Treg也具有更高的Foxp3表达,表明更高的抑制活性,并且我们随后将CD39用作etrog的标记物。我们的进一步研究表明,基于肿瘤中CD39推定etreg的比例,可结肠肿瘤可分为两种肿瘤组。该物业与肿瘤微卫星状况和肿瘤阶段无关,这是预测癌症疾病进展的重要因素。在对四十四次结肠癌患者的一项前瞻性研究中,我们还表明,在肿瘤浸润的Treg中具有高CD39表达的患者在累积癌症的癌症的存活方面对患者结果不太有利的患者结果。该研究在结肠癌中揭示了肿瘤浸润的Treg的新亚群,并表明CD39可以是微卫星稳定的结肠肿瘤患者的潜在治疗靶标,这通常是检查点阻断治疗的难治性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号